Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613229 | 1.00 | LMNA (0.33) | LMNAMAPK1HTTPPARGPPARA | |
| SCHEMBL19272914 | 0.90 | PPARG (0.31) | LMNAMAPK1HTTPPARGPPARA | |
| SCHEMBL29613166 | 0.89 | PDE4B (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18424750 | 0.89 | PDE4B (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19270712 | 0.83 | REN (0.38) | — | |
| SCHEMBL29613292 | 0.81 | CYP2C9 (0.36) | MAPK1PPARGPPARAHTR2AHTR2C | |
| SCHEMBL19252796 | 0.81 | CYP2C9 (0.36) | MAPK1PPARGPPARAHTR2AHTR2C | |
| SCHEMBL18424748 | 0.79 | LMNA (0.34) | LMNAMAPK1HTTPPARGPPARA | |
| SCHEMBL18425287 | 0.73 | PDE4B (0.48) | LMNAMAPK1HTTKDM4EALDH1A1 | |
| SCHEMBL19252777 | 0.72 | HTR2C (0.39) | MAPK1PPARGPPARAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071447-B | Tetracyclic pyridinone compounds as antiviral agents | 诺华股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| EP-3416946-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-10093673-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2018-10-09 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| WO-2017140821-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | LMNA 1780/4885MAPK1 1050/4885HTT 2916/4885 |
| US-10093673-B2 | Tetracyclic pyridone compounds as antivirals | PNPO, HAVCR2, TYMP | LMNA 1780/4885MAPK1 1050/4885HTT 2916/4885 |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | LMNA 1780/4885MAPK1 1050/4885HTT 2916/4885 |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | LMNA 1780/4885MAPK1 1050/4885HTT 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.